BACKGROUND: This analysis updates and extends efficacy estimates of the PEPI-Malawi trial through age 24 months at study completion in September 2009. METHODS:Infants of breastfeeding HIV-infected women were randomized at birth to the following: (1) single-dose nevirapine (NVP) + 1-week zidovudine (ZDV) (control); (2) control + extended daily NVP (ExtNVP) through 14 weeks; (3) control + extended daily NVP + ZDV (ExtNVP/ZDV) through 14 weeks. We estimated rates of HIV infection, death and HIV infection, or death using Kaplan-Meier analysis. RESULTS: This analysis includes 3126 infants uninfected at birth as follows: 1004 control, 1071 ExtNVP, and 1051 ExtNVP/ZDV. By 9 months, HIV infection rates were 5.0% in ExtNVP, 6.0% in ExtNVP/ZDV, and 11.1% in control (P < 0.001 comparing extended regimens with control). At age 24 months, HIV infection rates had risen to ~11% in the extended arms compared with 15.6% in the controls (P < 0.05). The rates of HIV infection or death were also significantly lower in extended arms. There were no differences in severe adverse events with the exception of higher possibly related events in the ExtNVP/ZDV arm. CONCLUSIONS: Daily infant antiretroviral prophylaxis reduces postnatal HIV infection by ~70% during the period of prophylaxis. But continued HIV transmission after prophylaxis stops suggests more prolonged infant prophylaxis is needed.
RCT Entities:
BACKGROUND: This analysis updates and extends efficacy estimates of the PEPI-Malawi trial through age 24 months at study completion in September 2009. METHODS:Infants of breastfeeding HIV-infectedwomen were randomized at birth to the following: (1) single-dose nevirapine (NVP) + 1-week zidovudine (ZDV) (control); (2) control + extended daily NVP (ExtNVP) through 14 weeks; (3) control + extended daily NVP + ZDV (ExtNVP/ZDV) through 14 weeks. We estimated rates of HIV infection, death and HIV infection, or death using Kaplan-Meier analysis. RESULTS: This analysis includes 3126 infants uninfected at birth as follows: 1004 control, 1071 ExtNVP, and 1051 ExtNVP/ZDV. By 9 months, HIV infection rates were 5.0% in ExtNVP, 6.0% in ExtNVP/ZDV, and 11.1% in control (P < 0.001 comparing extended regimens with control). At age 24 months, HIV infection rates had risen to ~11% in the extended arms compared with 15.6% in the controls (P < 0.05). The rates of HIV infection or death were also significantly lower in extended arms. There were no differences in severe adverse events with the exception of higher possibly related events in the ExtNVP/ZDV arm. CONCLUSIONS: Daily infant antiretroviral prophylaxis reduces postnatal HIV infection by ~70% during the period of prophylaxis. But continued HIV transmission after prophylaxis stops suggests more prolonged infant prophylaxis is needed.
Authors: Roger L Shapiro; Douglas Kitch; Anthony Ogwu; Michael D Hughes; Shahin Lockman; Kathleen Powis; Sajini Souda; Claire Moffat; Sikhulile Moyo; Kenneth McIntosh; Erik van Widenfelt; Sheryl Zwerski; Loeto Mazhani; Joseph Makhema; Max Essex Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Margaret L McNairy; Chloe A Teasdale; Wafaa M El-Sadr; Vidya Mave; Elaine J Abrams Journal: Curr Opin HIV AIDS Date: 2015-11 Impact factor: 4.283
Authors: Julie A E Nelson; Ali Fokar; Michael G Hudgens; Kara J Compliment; Justin Tyler Hawkins; Gerald Tegha; Deborah D Kamwendo; Dumbani Kayira; Innocent A Mofolo; Athena P Kourtis; Denise J Jamieson; Charles M Van Der Horst; Susan A Fiscus Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: Amanda H Corbett; Dumbani Kayira; Nicole R White; Nicole L Davis; Athena P Kourtis; Charles Chasela; Francis Martinson; Grace Phiri; Bonaface Musisi; Deborah Kamwendo; Michael G Hudgens; Mina C Hosseinipour; Julie Ae Nelson; Sascha R Ellington; Denise J Jamieson; Charles van der Horst; Angela Kashuba Journal: Antivir Ther Date: 2014-01-24
Authors: Sheree R Schwartz; Newton Kumwenda; Johnstone Kumwenda; Shu Chen; Lynne M Mofenson; Allan W Taylor; Mary Glenn Fowler; Taha E Taha Journal: Matern Child Health J Date: 2016-03
Authors: Andrew D Redd; Sarah K J Wendel; Andrew F Longosz; Jessica M Fogel; Sufia Dadabhai; Newton Kumwenda; Jin Sun; Michael P Walker; Daniel Bruno; Craig Martens; Susan H Eshleman; Stephen F Porcella; Thomas C Quinn; Taha E Taha Journal: AIDS Date: 2015-07-31 Impact factor: 4.177